Publications

The Mistletoe and Breast Cancer (MAB) Study: A UK Mixed-Phase, Pilot, Placebo-Controlled, Double-Blind, Randomised Controlled Trial.

Duncan LJ. et al, (2025), Cancers (Basel), 17

Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.

Abraham JE. et al, (2025), Nat Commun, 16

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.

Abraham JE. et al, (2024), Nature, 629, 1142 - 1148

Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.

Braybrooke J. et al, (2024), Lancet, 403

Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel.

Copson ER. et al, (2023), Breast, 72

Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer.

Bahl A. et al, (2022), Breast, 66, 69 - 76

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).

Joffe JK. et al, (2022), J Clin Oncol, 40, 2468 - 2478

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.

Early Breast Cancer Trialists’ Collaborative group (EBCTCG) ., (2021), Lancet Oncol, 22, 1139 - 1150

Real-world outcomes in patients receiving neo-adjuvant chemotherapy for early-stage breast cancer

McDonald C. et al, (2021), CANCER RESEARCH, 81

Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST).

Joffe JK. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.

Turner NC. et al, (2020), Lancet Oncol, 21, 1296 - 1308

Trastuzumab Beyond Progression in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: UK Practice now and in the Future.

Robinson T. et al, (2020), Clin Oncol (R Coll Radiol), 32, 636 - 638

Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery.

Wilson TG. et al, (2020), Clin Oncol (R Coll Radiol), 32, 390 - 396

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

Kos Z. et al, (2020), NPJ Breast Cancer, 6

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

Amgad M. et al, (2020), NPJ Breast Cancer, 6

Search results (82)